Difluprednate 0.05% versus Prednisolone Acetate 1% for Endogenous Anterior Uveitis: Pooled Efficacy Analysis of Two Phase 3 Studies

REFERENCES

• Nussenblatt RB. The natural history of uveitis. Int Ophthalmol. 1990;14:303–308.
   PubMed Web of Science ®Google Scholar
• Durrani OM, Tehrani NN, Marr JE, et al. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004;88:1159–1162.
   PubMed Web of Science ®Google Scholar
• Guly CM, Forrester JV. Investigation and management of uveitis. Bmj. 2010;341:c4976.
   PubMed Web of Science ®Google Scholar
• Weston A Systemic associations and management of uveitis. http://www.optometry.co.uk/uploads/articles/cet-2015/september_26_2015_c-42116.pdf.2015. Accessed October 29, 2015.
   Google Scholar
• Herman DC. Endogenous uveitis: current concepts of treatment. Mayo Clin Proc. 1990;65:671–683.
   PubMed Web of Science ®Google Scholar
• American Academy of Ophthalmology. Uveitis. Practising ophthalmologist’s curriculum. https://www.aao.org/assets/8f1bff17-b02c-4750-b05c-cc202843cf2a/635222149312630000/uveitis-2014-pdf.2014 [Accessed October 19 2015.]
   Google Scholar
• Lee RWJ, Schewitz LP, Raveney BJE, et al. Steroid sensitivity in uveitis. In: Pleyer U, Forrester JV, eds. Uveitis And Immunological Disorders. Heidelberg, Germany: Springer-Verlag Berlin; 2009:45–52.
   Google Scholar
• Anesi SD, Foster SC. Anterior uveitis: etiology and treatment. Advanced Ocular Care. 2011;32–34.
   Google Scholar
• Vandenbroeck S, De Geest S, Dobbels F, et al. Prevalence and correlates of self-reported nonadherence with eye drop treatment: the Belgian compliance study in ophthalmology (BCSO). J Glaucoma. 2011;20:414–421.
   PubMed Web of Science ®Google Scholar
• Tajika T, Waki M, Tsuzuki M, et al. Pharmacokinetic features of difluprednate ophthalmic emulsion in rabbits as determined by glucocorticoid receptor-binding bioassay. J Ocul Pharmacol Ther. 2011;27:29–34.
   PubMed Web of Science ®Google Scholar
• Bodor N, Harget AJ, Phillips EW. Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach. J Med Chem. 1983;26:318–328.
   PubMed Web of Science ®Google Scholar
• Jamal KN, Callanan DG. The role of difluprednate ophthalmic emulsion in clinical practice. Clin Ophthalmol. 2009;3:381–390.
   PubMedGoogle Scholar
• DUREZOL. DUREZOL prescribing information. http://ecatalog.alcon.com/PI/Durezol_us_en.pdf.2013 Accessed October 29, 2015.
   Google Scholar
• Foster CS, Davanzo R, Flynn TE, et al. Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. J Ocul Pharmacol Ther. 2010;26:475–483.
   PubMed Web of Science ®Google Scholar
• Sheppard JD, Toyos MM, Kempen JH, et al. Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study. Invest Ophthalmol Vis Sci. 2014;55:2993–3002.
   PubMed Web of Science ®Google Scholar
• PRED FORTE. PRED FORTE prescribing information. http://www.allergan.com/assets/pdf/pred_forte_pi.pdf.2013 Accessed October 29, 2015.
   Google Scholar
• Díaz-Valle D, Méndez-Fernández R. Treatment strategies in non-infectious uveitis: general concepts. In: Mesquida M, ed. Advances In The Treatment Of Noninfectious Uveitis With Biologics: Anti-TNF And Beyond. United States, CA: OMICS Group; 2014.
   Google Scholar
• Biswas J, Ganeshbabu TM, Raghavendran SR, et al. Efficacy and safety of 1% rimexolone versus 1% prednisolone acetate in the treatment of anterior uveitis–a randomized triple masked study. Int Ophthalmol. 2004;25:147–153.
   PubMedGoogle Scholar
• Foster CS, Alter G, DeBarge LR, et al. Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis. Am J Ophthalmol. 1996;122:171–182.
   PubMed Web of Science ®Google Scholar
• Eilon LA, Walker SR. Clinical evaluation of clobetasone butyrate eye drops in the treatment of anterior uveitis and its effects on intraocular pressure. Br J Ophthalmol. 1981;65:644–647.
   PubMed Web of Science ®Google Scholar
• Hunter PJ, Fowler PD, Wilkinson P. Treatment of anterior uveitis. Comparison of oral oxyphenbutazone and topical steroids. Br J Ophthalmol. 1973;57:892–896.
   PubMed Web of Science ®Google Scholar
• Dunne JA, Jacobs N, Morrison A, et al. Efficacy in anterior uveitis of two known steroids and topical tolmetin. Br J Ophthalmol. 1985;69:120–125.
   PubMed Web of Science ®Google Scholar
• Dunne JA, Travers JP. Double-blind clinical trial of topical steroids in anterior uveitis. Br J Ophthalmol. 1979;63:762–767.
   PubMed Web of Science ®Google Scholar
• Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol etabonate US uveitis study group. Am J Ophthalmol. 1999;127:537–544.
   PubMedGoogle Scholar
• Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995;26:233–236.
   PubMedGoogle Scholar
• Stringer W, Bryant R. Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%. Clin Ophthalmol. 2010;4:1119–1124.
   PubMedGoogle Scholar
• Dart J. Corneal toxicity: the epithelium and stroma in iatrogenic and factitious disease. Eye (Lond). 2003;17:886–892.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Labbe A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312–334.
   PubMed Web of Science ®Google Scholar
• Tripathi BJ, Tripathi RC, Kolli SP. Cytotoxicity of ophthalmic preservatives on human corneal epithelium. Lens Eye Toxic Res. 1992;9:361–375.
   PubMedGoogle Scholar
• US FDA. Dermatologic and ophthalmic drugs advisory committee briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4358b1-02-Sirion.pdf.2008 Accessed February 12, 2016.
   Google Scholar
• Ohno S, Mochizuki M, Usui M, et al. A phase III, non-inferiority study of difluprednate ophthalmic emulsion (DFBA), 0.05% in the treatment of anterior uveitis. Invest Ophthalmol Vis Sci. 2007;48:3904.
   Google Scholar
• Mochizuki M, Ohno S, Usui M, et al. A phase III, open-label, clinical study of difluprednate ophthalmic emulsion (DFBA), 0.05% in the treatment of severe refractory anterior uveitis. Invest Ophthalmol Vis Sci. 2007;48:3905.
   PubMedGoogle Scholar
• Sheppard J, Joshi A, Betts KA, et al. Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis in the VISUAL-1 and VISUAL-2 trials. JAMA Ophthalmol. 2017. doi:10.1001/jamaophthalmol.2017.0603.
   PubMed Web of Science ®Google Scholar